晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析

doi:10.3969/j.issn.1005-4979.2012.02.001

摘要/Abstract

摘要： 晚期口腔颌面-头颈部鳞癌的治疗仍然是个巨大的挑战。尽管传统的手术、放疗及化疗已取得了很大的进展，但晚期口腔颌面?鄄头颈部鳞癌的预后仍然较差，分子靶向药物为此带来了新的希望。目前针对口腔颌面?鄄头颈部鳞癌的靶向治疗的靶点主要有表皮生长因子受体及血管内皮生长因子受体。前者的代表药物有西妥昔单抗及尼妥珠单抗，他们无论是单药治疗，还是与放化疗结合治疗，均表现出了良好的前景；后者的代表药物主要是贝伐单抗，也已经进行到临床III期实验。靶向治疗为晚期口腔颌面?鄄头颈部鳞癌的治疗提供了新的机遇。

关键词: 口腔颌面-头颈部鳞癌, 靶向治疗, 表皮生长因子受体, 血管内皮生长因子受体, 西妥昔单抗, 尼妥珠单抗, 贝伐单抗

Abstract: The treatment of advanced oral and maxillofacial-head and neck squamous cell carcinoma(SCCHN) is still a challenge in the section of oncology in oral and maxillofacial surgery. Although the traditional treatments like radical surgical operation combined with radiotherapy or chemotherapy has progressed a lot recently, the prognosis of the advanced SCCHN is still poor. However, the progress of target drugs brings hope for it. Two primary strategies have emerged that account for most of the success of current targeted therapies: one is epidermal growth factor receptor (EGFR), and the other is vascular endothelial growth factor (VEGF) receptor. The typical drugs to block EGFR are cetuximab and nimotuzumab, both of them have demonstrated survival benefits across whatever monotherapy, or multitherapy with radiotherapy or chemotherapy. The typical drug to block VEGF is bevacizumab, which is now proceeding through Phase III clinical trial. The targeted therapy is a new choice for the advanced SCCHN.

Key words: squamous cell carcinoma of oral and maxillofacial-head and neck, targeted therapy, epidermal growth factor receptor（EGFR）, vascular endothelial growth factor receptor （VEGF）, cetuximab, nimotuzumab, bevacizumab

中图分类号:

R739.81

郭　伟. 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J]. 《口腔颌面外科杂志》, 2012, 22(2): 77-81.

GUO Wei. Advances of Targeted Therapies in Squamous Cell Carcinoma of Oral and Maxillofacial-Head and Neck[J]. 《Journal of Oral and Maxillofacial Surgery》, 2012, 22(2): 77-81.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2012/V22/I2/77

参考文献

[1] Stewart BW, Kleihues PE. International Agency for Research 2003[J]. Acta Oncological, 2003, 43(5): 506-507.

[2] Hoffman HT, Karnell LH, Funk GF, et al. The national cancer data base report on cancer of the head and neck[J]. Arch Otolaryngol Head Neck Surg, 1998, 124(9): 951-962．

[3] Khuri FR, Shin DM, Glisson BS, et al.Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions[J]. Semin Oncol, 2000, 27(4 Suppl 8):25-33.

[4] 邱蔚六，张震康.口腔颌面外科学[M]. 5版.北京：人民卫生出版社，2003:219-220.

[5] Soria JC, Kim ES, Fayette J, et al. Chemoprevention of lung cancer[J]. Lancet Oncol, 2003, 4(11): 659-669.

[6] Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer[J]. Gene,2006,366(1):2-16.

[7] Lemmon MA, Bu Z, Ladbury JE, et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer [J]. EMBO J, 1997, 16(2):281-294.

[8] Garrett TP, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha [J]. Cell, 2002, 110(6):763-773.

[9] Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma[J]. Cancer Res,2002, 62(124):7350-7356.

[10] Grandis JR, Melhem MF, Barnes EL, et al. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck[J]. Cancer,1996,78(6):1284-1292.

[11] Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival[J]. J Natl Cancer Inst,1998, 90(11): 824-832.

[12] Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin[J]. J Clin Oncol, 2000,18(4):904-914.

[13] Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck[J]. Cancer Res, 1999, 59(8):1935-1940.

[14] Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol, 2003,21(14):2787-2799.

[15] Kang X, Patel D, Ng S, et al. High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab [J]. J Clin Oncol, 2007, 25(18S):3041.

[16] Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-rRefractory metastatic and/or recurrent squamous cell carcinoma of the head and neck[J]. J Clin Oncol, 2005, 23(24):5568-5577.

[17] Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]. N Engl J Med, 2008, 359(11):1116-1127.

[18] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med,2006,354(6):567-578.

[19] Vermorken JB, Trigo J, Hitt R, et al.Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy[J]. J Clin Oncol,2007,25(16):2171-2177.

[20] León X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy[J]. Clin Oncol (R Coll Radiol),2005,17(6):418-424.

[21] Crombet-Ramos T, Rak J, Pérez R, et al. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody[J]. Int J Cancer, 2002, 101(6):567-575.

[22] Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis[J]. Cancer Res, 2001,61(13):5090-5101.

[23] Diaz Miqueli A, Blanco R, Garcia B, et al. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities[J]. Hybridoma(Larchmt), 2007,26(6):423-431.

[24] Rodríguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous cell carcinoma of the head and neck[J]. Cancer Biol Ther, 2010, 9(5):343-349.

[25] Babu KG, Viswanath L, Reddy BK, et al. An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study[J]. J Clin Oncol , 2010,28 (15 S): 5530.

[26] Allan DG. Nimotuzumab: evidence of clinical benefit without rash[J].Oncologist, 2005,10(9):760-761.

[27] Mahadevan V,Hart I R.Metastasis and angiogenesis[J]. Acta Oncol, 1990, 29(1):97-103.

[28] Fidler IJ，Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis[J].Cell, 1994, 79(2):185-188.

[29] Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer[J]. Semin Oncol,2003,30(3 Suppl):39-50.

[30] Folkman J. Role of angiogenesis in tumor growth and metastasis[J]. Semin Oncol. 2002,29(6 Suppl):15-18.

[31] Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor[J]. Semin Oncol,2002,29(6 Suppl 16):3-9.

[32] Bock JM, Sinclair LL, Bedford NS, et al. Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck[J]. Arch Otolaryngol Head Neck Surg, 2008,134(4):355-362

[33] Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck[J]. Cancer, 2009,115(5):922-935.

[34] Baserga R, Peruzzi F, Reiss K.The IGF-1 receptor in cancer biology[J]. Int J Cancer,2003,107(6):873-877.

[35] Giaccone G, Zucali PA. Src as a potential therapeutic target in non-small-cell lung cancer[J]. Ann Oncol, 2008, 19(7):1219-1223.

[36] Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-3548285) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells[J]. Clin Cancer Res, 2005, 11(19Pt1):6924-6932.

[37] Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer[J]. J Cancer Res, 1993, 53(19):4477-4480.

选择文件类型/文献管理软件名称

选择包含的内容